Letairis ambrisentan: Additional Phase III data

Combined Phase III data from the ARIES-I and ARIES-II trials showed that ambrisentan improved the 6MWD at week 12 improved by 58 meters from baseline in patients with idiopathic PAH (IPAH) (p<0.001) a...